All In Biotech

Drug Trial Radar · NCT05182034

Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

A Multi-center, Randomized, Double-Blinded, Active-Controlled, Phase II Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis

Last checked: Nov 20, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

94

Actual

Start

Feb 24, 2022

Primary completion

Oct 17, 2023

Study completion Oct 17, 2023

Sponsor

Lead sponsor
Medipost Co Ltd.Industry
Sponsor type
Industry
First posted
Jan 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.

Conditions

  • Knee Osteoarthritis

Interventions

  • SMUP-IA-01(low dose)Biological

    A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)

  • SMUP-IA-01(mid dose)Biological

    A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)

  • Active Control Group Sodium chlorideDrug

    A single knee administration of Sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baselineTime frame: Baseline, 52 week

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Seoul Nation University Bundang Hospital

    Gyeonggi-do, South Korea

  • Gangnam Severance Hospital

    Seoul, South Korea

  • Korea University Anam Hospita

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.